Rachelle A. Victorio

Rachelle A. Victorio

Auto-generated profile, based on publicly available information

Rachelle A. Victorio

Department of Medicine, Brigham and Women’s Hospital, Boston, MA (K.S., M.L.B., W.H.B., A.K.C., M.H., R.A.V., D.Q., A.W., E.P., C.A.M.).

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
WZWandi Zhu
Wandi Zhu
SGShihui Guo
Shihui Guo
MHMax Homilius
Max Homilius
CNCissy Nsubuga
Cissy Nsubuga
SWShane H. Wright
Shane H. Wright
CMCalum A. MacRae
Calum A. MacRae
Hematopoietic cell selection based on PIEZO1 expression drives thrombosis risk in type 2 diabetes.

1 August 2022 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
HJHannah N. De Jong
Hannah N. De Jong
FDFrederick E. Dewey
Frederick E. Dewey
PCPablo Cordero
Pablo Cordero
RVRachelle A. Victorio
Rachelle A. Victorio
AKAnna Kirillova
Anna Kirillova
EAEuan A. Ashley
Euan A. Ashley
Background: The study of hypertrophic cardiomyopathy (HCM) can yield insight into the mechanisms underlying the complex trait of cardiac hypertrophy. To date, most genetic variants associated with HCM have been found in sarcomeric genes. Here, we describe a novel HCM-associated variant in the noncanonical Wnt signaling interactor WTIP (Wilms tumor interacting protein) and provide evidence of a role for WTIP in complex disease. Methods: In a family affected by HCM, we used exome sequencing and identity-by-descent analysis to identify a novel variant in WTIP (p.Y233F). We knocked down WTIP in isolated neonatal rat ventricular myocytes with lentivirally delivered short hairpin ribonucleic acids and in Danio rerio via morpholino injection. We performed weighted gene coexpression network analysis for WTIP in human cardiac tissue, as well as association analysis for WTIP variation and left ventricular hypertrophy. Finally, we generated induced pluripotent stem cell–derived cardiomyocytes from patient tissue, characterized size and calcium cycling, and determined the effect of verapamil treatment on calcium dynamics. Results: WTIP knockdown caused hypertrophy in neonatal rat ventricular myocytes and increased cardiac hypertrophy, peak calcium, and resting calcium in D rerio . Network analysis of human cardiac tissue indicated WTIP as a central coordinator of prohypertrophic networks, while common variation at the WTIP locus was associated with human left ventricular hypertrophy. Patient-derived WTIP p.Y233F-induced pluripotent stem cell–derived cardiomyocytes recapitulated cellular hypertrophy and increased resting calcium, which was ameliorated by verapamil. Conclusions: We demonstrate that a novel genetic variant found in a family with HCM disrupts binding to a known Wnt signaling protein, misregulating cardiomyocyte calcium dynamics. Further, in orthogonal model systems, we show that expression of the gene WTIP is important in complex cardiac hypertrophy phenotypes. These findings, derived from the observation of a rare Mendelian disease variant, uncover a novel disease mechanism with implications across diverse forms of cardiac hypertrophy.

14 August 2026 in Circulation Research
Verified
Journal Article
Open access
QGQianyun Ge
Qianyun Ge
KSKusumika Saha
Kusumika Saha
MBMicah L. Burch
Micah L. Burch
WBWillow H. Battista
Willow H. Battista
AKAshmita Kc
Ashmita Kc
WZWandi Zhu
Wandi Zhu
BACKGROUND: Variants in PRKAG2 cause hypertrophic cardiomyopathy and conduction disturbances. Although prior studies associated PRKAG2 -related hypertrophy with increased glycogen storage, many hypertrophic cardiomyopathy phenotypes remain unexplained. We aimed to uncover how PRKAG2 variants induce myocyte hypertrophy and electrical changes during early cardiac development. METHODS: We generated transgenic zebrafish expressing wild-type or pathogenic variant Prkag2 under a myocardium-specific promoter, Tg( cmcl2 : Prkag2 WT ) (Tg WT ) and Tg( cmcl2 : Prkag2 R299Q ) (Tg R299Q ), respectively, and examined cardiac electrophysiology, contractile function, and cytoarchitecture during cardiogenesis and in adult hearts. RESULTS: Tg R299Q fish showed hypertrophic cardiomyocytes and progressive contractile abnormalities, recapitulating human hypertrophic cardiomyopathy phenotypes. Cardiomyocyte glycogen was elevated in adult but not embryonic hearts. Despite the absence of glycogen accumulation at 6 days post-fertilization, Tg R299Q hearts showed electrical abnormalities, including reduced conduction velocity and prolonged action potential and Ca 2+ transient durations, compared to Tg WT and wild-type (Tübingen/AB [TuAB]). We observed decreased AMPK (AMP-activated protein kinase) phosphorylation in the Tg R299Q hearts. However, AMPK activation did not rescue the electrophysiological abnormalities in Tg R299Q . Proximity ligation assays and coimmunoprecipitation identified a physical interaction between AMPKγ2 and myosin, enhanced by the R299Q variant and accompanied by increased AMPKγ2 localization to the myofilament. NCX (Na + /Ca 2+ exchanger) inhibition increased Ca 2+ duration and diastolic Ca 2+ in Tg WT but not Tg R299Q hearts, indicating reduced free cytosolic Ca 2+ for NCX-mediated extrusion in Tg R299Q . These findings suggest that enhanced AMPKγ2-myosin interaction may promote myofilament Ca 2 + retention, thereby prolonging Ca 2 + transient duration and action potential duration in the mutant. Notably, the myosin inhibitor mavacamten reduced AMPKγ2-myosin interaction in Tg R299Q hearts, and both mavacamten and vmhcl knockdown rescued the early electrophysiological abnormalities. CONCLUSIONS: The PRKAG2 variant altered cardiac excitability, contractility, and Ca 2+ handling during cardiogenesis, independent of glycogen accumulation. Enhanced interactions between AMPKγ2 and myosin contributed to these early changes. Our study revealed a novel link between cellular energy sensing and contractile machinery, with therapeutic potential for modulating contractile function in cardiomyopathies.

23 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
QGQianyun Ge
Qianyun Ge
KSKusumika Saha
Kusumika Saha
MBMicah L. Burch
Micah L. Burch
WBWillow H. Battista
Willow H. Battista
KAKc Ashmita
Kc Ashmita
WZWandi Zhu
Wandi Zhu
Introduction: Variants in PRKAG2 cause hypertrophic cardiomyopathy (HCM) and conduction disturbances. While prior studies associated PRKAG2 -related hypertrophy with increased glycogen storage, many HCM phenotypes remain unexplained. We aimed to uncover how PRKAG2 variants induce myocyte hypertrophy and electrical changes during early cardiac development. Methods: We generated transgenic zebrafish expressing wild-type (Tg WT ) or pathogenic variant (Tg R299Q ) Prkag2 cDNA under a myocardium-specific promoter, and examined cardiac electrophysiology, contractile function, and cytoarchitecture during cardiogenesis and in adult hearts. Results: Tg R299Q fish showed hypertrophic cardiomyocytes and progressive contractile abnormalities, recapitulating human HCM phenotypes. Cardiomyocyte glycogen was elevated in adult but not embryonic hearts. Despite the absence of glycogen accumulation at 6-day post-fertilization, Tg R299Q hearts showed electrical abnormalities, including reduced conduction velocity and prolonged action potential and Ca 2+ transient durations. We observed decreased AMPK phosphorylation in the Tg R299Q hearts. However, AMPK activation did not rescue the electrophysiological abnormalities in Tg R299Q . Proximity ligation assays and co-immunoprecipitation identified a physical interaction between AMPKγ2 and myosin, enhanced by the R299Q variant and accompanied by increased AMPKγ2 localization to the myofilament. Na⁺/Ca²⁺ exchanger (NCX) inhibition increased Ca 2+ duration and diastolic Ca 2+ in Tg WT but not Tg R299Q hearts, indicating reduced free cytosolic Ca 2+ for NCX-mediated extrusion in Tg R299Q . These findings suggest that enhanced AMPKγ2-myosin interaction may promote myofilament Ca²⁺ retention, thereby prolonging Ca²⁺ transient duration and APD in the mutant. Notably, the myosin inhibitor mavacamten reduced AMPKγ2-myosin interaction in Tg R299Q hearts, and both mavacamten and vmhcl knockdown rescued the early electrophysiological abnormalities. Conclusions: The PRKAG2 variant altered cardiac excitability, contractility, and Ca 2+ handling during cardiogenesis, independent of glycogen accumulation. Enhanced interactions between AMPKγ2 and myosin contributed to these early changes. Our study revealed a novel link between cellular energy sensing and contractile machinery, with therapeutic potential for modulating contractile function in cardiomyopathies.